Guido Lancman, MD, Discusses Promising Multiple Myeloma Treatments

December 13, 2020
Guido Lancman, MD

The hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai highlighted multiple myeloma treatments that he believes have shown promise over the past year.

In an interview with CancerNetwork®, Guido Lancman, MD, hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai, spoke about multiple myeloma treatments that he believes have shown promise over the past year.

Transcription:

So, there's a lot of new developments in multiple myeloma that are very exciting. CAR T(-cell therapy) has shown really dramatic response rates in heavily treated patients. Bispecific antibodies are also in a slightly earlier stage of their development but are also showing very high response rates with really excellent tolerability. So, I'm pretty excited to see what the future holds for CAR T and bispecifics.